Good month. 40 papers. I think the main takeaway here is the buprenorphine waiver required for U.S. providers to treat their patients with buprenorphine – it needs to go. It is an archaic and absurd construct essentially invented by the US Supreme Court a century ago when the court decided “addiction is not a disease”.Read More
PubMed Update March 2019
43 new papers for March of 2019. 1) Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. Krieter P, Gyaw S, Crystal R, Skolnick P. J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115. [Epub ahead of print] Comments: Nalmefene has high affinity and >7h duration of effect. But not atRead More
PubMed Update January 2019
We start out 2019 with 42 new papers. The overarching theme is fentanyl – with some useful data really starting to emerge. Also several addressing surveillance-type issues, which is still badly needed and exciting work. We’ve also got the standard naloxone papers and a few weird drugs (e.g. tramadol and kratom). 1) Drugs Most Frequently InvolvedRead More